Compounds for the treatment of cancer and inflammatory disease

1. A compound of Formula VIb1:

or a pharmaceutically acceptable salt thereof,

wherein

R 1b1 is 2-pyridyl or NH 2 ;

R 8b1 is H;

R 9b1 is aryl, halo, or C(O)R 4 ;

R 4 is NR 6 R 7 ; and

R 6 and R 7 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, or R 6 and R 7 are combined to form a cyclic structure including the nitrogen atom to which they are both attached,

wherein each of the alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, and cyclic structure are optionally substituted with one or more substituents Q independently selected from (a) deuterium, cyano, halo, and nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more substituents Q a , and (c) —C(O)R a , —C(O)OR a , —C(O)NR b R c , —C(NR a )NR b R c , —OR a , —OC(O)R a , —OC(O)OR a , —OC(O)NR b R c , —OC(═NR a )NR b R c , —OS(O)R a , —OS(O) 2 R a , —OS(O)NR b R c , —OS(O) 2 NR b R c , —NR b R c , —NR a C(O)R d , —NR a C(O)OR d , —NR a C(O)NR b R c , —NR a C(═NR d )NR b R c , —NR a S(O)R d , —NR a S(O) 2 R d , —NR a S(O)NR b R c , —NR a S(O) 2 NR b R c , —SR a , —S(O)R a , —S(O) 2 R a , —S(O)NR b R c , and —S(O) 2 NR b R c ,

wherein each R a , R b , R c , and R d is independently (i) hydrogen or deuterium or (ii) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q a ; or (iii) R b and R c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q a ;

wherein each Q a is independently selected from the group consisting of (a) deuterium, cyano, halo, and nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Re, —C(O)OR e , —C(O)NR f R g , —C(NR e )NR f R g , —OR e , —OC(O)R e , —OC(O)OR e , —OC(O)NR f R g , —OC(═NR e )NR f R g , —OS(O)R e , —OS(O) 2 R e , —OS(O)NR f R g , —OS(O) 2 NR f R g , —NR f R g , —NR e C(O)R h , —NR e C(O)OR f , —NR e C(O)NR f R g , —NR e C(═NR h )NR f R g , —NR e S(O)R h , —NR e S(O) 2 R h , —NR e S(O)NR f R g , —NR e S(O) 2 NR f R g , —SR e , —S(O)R e , —S(O) 2 R e , —S(O)NR f R g , and —S(O) 2 NR f R g ;

wherein each R e , R f , R g , and R h is independently (i) hydrogen or deuterium or (ii) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R f and R g together with the N atom to which they are attached form heterocyclyl;

wherein heteroaryl is a monocyclic or multicyclic aromatic ring system of about 5 to about 15 atoms, wherein one or more of the atoms in the ring system is nitrogen, oxygen, or sulfur; and

wherein heterocyclyl is a monocyclic or multicyclic non-aromatic ring system of about 5 to about 15 atoms, wherein one or more of the atoms in the ring system is nitrogen, oxygen, or sulfur.

2. A method of treating cancer, comprising administering to a subject the compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the cancer is leukemia, hepatocellular carcinoma, prostate cancer, pancreatic cancer, ovarian cancer, or glioblastoma.

3. The method of claim 2 , wherein the cancer is hepatocellular carcinoma, prostate cancer, pancreatic cancer, ovarian cancer, or glioblastoma.

4. The method of claim 3 , wherein the cancer is pancreatic cancer.

5. A method of treating an inflammatory disease, comprising administering to a subject the compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the inflammatory disease is gastritis, schistosomiasis, cholangitis, chronic cholecystitis, pelvic inflammatory disease, chronic cervicitis, osteomyelitis, inflammatory bowel disease, reflux esophagitis, Barrett's esophagus, bladder inflammation (cystitis), asbestosis, silicosis, gingivitis, lichen planus, pancreatitis, protease mutation, lichen sclerosis, slaladenitis, bronchitis, Sjogren syndrome or Hashimoto's thyroiditis.

6. A pharmaceutical composition, comprising an effective amount of the compound or pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable carrier.

7. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

8. A method of treating cancer, comprising administering to a subject the compound or pharmaceutically acceptable salt of thereof claim 7 , wherein the cancer is leukemia, hepatocellular carcinoma, prostate cancer, pancreatic cancer, ovarian cancer, or glioblastoma.

9. The method of claim 8 , wherein the cancer is hepatocellular carcinoma, prostate cancer, pancreatic cancer, ovarian cancer, or glioblastoma.

10. The method of claim 9 , wherein the cancer is pancreatic cancer.

11. A method of treating an inflammatory disease, comprising administering to a subject the compound or pharmaceutically acceptable salt thereof of claim 7 , wherein the inflammatory disease is gastritis, schistosomiasis, cholangitis, chronic cholecystitis, pelvic inflammatory disease, chronic cervicitis, osteomyelitis, inflammatory bowel disease, reflux esophagitis, Barrett's esophagus, bladder inflammation (cystitis), asbestosis, silicosis, gingivitis, lichen planus, pancreatitis, protease mutation, lichen sclerosis, slaladenitis, bronchitis, Sjogren syndrome, or Hashimoto's thyroiditis.

12. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of claim 7 and a pharmaceutically acceptable carrier.

13. The method of claim 2 , wherein the cancer is leukemia.

14. The method of claim 13 , wherein the leukemia is chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or acute myeloblasts leukemia (AML).

15. The method of claim 8 , wherein the cancer is leukemia.

16. The method of claim 15 , wherein the leukemia is chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or acute myeloblasts leukemia (AML).